Mezzion Pharma Statistics
Total Valuation
Mezzion Pharma has a market cap or net worth of KRW 1.10 trillion. The enterprise value is 1.07 trillion.
Market Cap | 1.10T |
Enterprise Value | 1.07T |
Important Dates
The last earnings date was Friday, March 21, 2025.
Earnings Date | Mar 21, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Mezzion Pharma has 29.96 million shares outstanding. The number of shares has increased by 5.62% in one year.
Current Share Class | n/a |
Shares Outstanding | 29.96M |
Shares Change (YoY) | +5.62% |
Shares Change (QoQ) | +0.66% |
Owned by Insiders (%) | 9.59% |
Owned by Institutions (%) | 6.00% |
Float | 21.54M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 127.10 |
PB Ratio | 23.87 |
P/TBV Ratio | 24.74 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -55.07 |
EV / Sales | 124.56 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -56.22 |
Financial Position
The company has a current ratio of 1.57, with a Debt / Equity ratio of 0.04.
Current Ratio | 1.57 |
Quick Ratio | 1.12 |
Debt / Equity | 0.04 |
Debt / EBITDA | n/a |
Debt / FCF | -0.08 |
Interest Coverage | -47.54 |
Financial Efficiency
Return on equity (ROE) is -36.23% and return on invested capital (ROIC) is -16.05%.
Return on Equity (ROE) | -36.23% |
Return on Assets (ROA) | -10.76% |
Return on Invested Capital (ROIC) | -16.05% |
Return on Capital Employed (ROCE) | -30.21% |
Revenue Per Employee | 506.57M |
Profits Per Employee | -1.15B |
Employee Count | 17 |
Asset Turnover | 0.10 |
Inventory Turnover | 1.20 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -8.36% in the last 52 weeks. The beta is 0.48, so Mezzion Pharma's price volatility has been lower than the market average.
Beta (5Y) | 0.48 |
52-Week Price Change | -8.36% |
50-Day Moving Average | 29,564.00 |
200-Day Moving Average | 32,042.25 |
Relative Strength Index (RSI) | 73.91 |
Average Volume (20 Days) | 150,951 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Mezzion Pharma had revenue of KRW 8.61 billion and -19.48 billion in losses. Loss per share was -653.04.
Revenue | 8.61B |
Gross Profit | 1.91B |
Operating Income | -14.30B |
Pretax Income | -14.53B |
Net Income | -19.48B |
EBITDA | -13.34B |
EBIT | -14.30B |
Loss Per Share | -653.04 |
Balance Sheet
The company has 28.62 billion in cash and 1.62 billion in debt, giving a net cash position of 27.00 billion or 901.14 per share.
Cash & Cash Equivalents | 28.62B |
Total Debt | 1.62B |
Net Cash | 27.00B |
Net Cash Per Share | 901.14 |
Equity (Book Value) | 46.06B |
Book Value Per Share | 1,537.30 |
Working Capital | 15.26B |
Cash Flow
In the last 12 months, operating cash flow was -18.49 billion and capital expenditures -590.49 million, giving a free cash flow of -19.08 billion.
Operating Cash Flow | -18.49B |
Capital Expenditures | -590.49M |
Free Cash Flow | -19.08B |
FCF Per Share | -636.77 |
Margins
Gross margin is 22.18%, with operating and profit margins of -166.05% and -226.17%.
Gross Margin | 22.18% |
Operating Margin | -166.05% |
Pretax Margin | -168.77% |
Profit Margin | -226.17% |
EBITDA Margin | -154.93% |
EBIT Margin | -166.05% |
FCF Margin | n/a |
Dividends & Yields
Mezzion Pharma does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -5.62% |
Shareholder Yield | -5.62% |
Earnings Yield | -1.77% |
FCF Yield | -1.74% |
Stock Splits
The last stock split was on April 5, 2022. It was a forward split with a ratio of 3.
Last Split Date | Apr 5, 2022 |
Split Type | Forward |
Split Ratio | 3 |
Scores
Mezzion Pharma has an Altman Z-Score of 19.76.
Altman Z-Score | 19.76 |
Piotroski F-Score | n/a |